

---

**From:** [REDACTED]  
**Sent:** Friday, 19 February 2021 2:33 PM  
**To:** Channing, Darrell; Bell, Simon  
**Cc:** Exemptions; [REDACTED]; [REDACTED]  
**Subject:** Medicines Australia – ACCC Authorisation AA1000486 – fortnightly report 6 February 2021 – 19 February 2021 [SEC=OFFICIAL]

Dear Simon/Darrell,

In relation to the ACCC Authorisation **AA1000486** (24 September 2020) and, specifically, in accordance with the Conditions of that Authorisation at paragraph 5.12, Medicines Australia provides the following fortnightly report on activities related to the Proposed Conduct.

In the period of 6 February 2021 to 19 February 2021, no meetings or discussions of the Medicines Australia/Generic and Biosimilar Medicines Association Working Group occurred and no decisions were made that fall under the Proposed Conduct.

Medicines Australia's next fortnightly update will cover the period of 20 February 2021 to 5 March 2021. Additional updates will be provided to the ACCC as required and in accordance with Medicines Australia's obligations under the authorisation.

We also consent to this email being published on the public register, with the appropriate privacy redactions.

This response was drafted in consultation with [REDACTED], CEO of Generic and Biosimilar Medicines Association.

Yours sincerely,

[REDACTED]  
[REDACTED]

Manager, Industry and Regulatory Policy  
Medicines Australia

17 Denison Street  
Deakin ACT 2600  
Australia

Main Office: [REDACTED]  
Mobile: [REDACTED]  
Email: [REDACTED]  
Web: [www.medicinesaustralia.com.au](http://www.medicinesaustralia.com.au)

